source
- FDA advisory panel debates allowing compounding pharmacies to produce seven peptidesThe FDA’s advisory committee spent two days reviewing whether compounding pharmacies should be permitted to manufacture a set of seven peptide products. The discussion involved both committee membe…
- STAT+: FDA staff reiterate concerns about Replimune skin cancer treatmentRegulators at the FDA have reiterated concerns that Replimmune does not have adequate data to support an approval of its investigational skin cancer treatment.